Medical Express A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found that Programmed Death-Ligand 1 (PD-L1), a protein best known for helping tumors evade immune attack, instead helped immunocompromised mice clear flu-infected lung cells and survive infection. The findings challenge long-standing assumptions about PD-L1’s role in the immune system. While cancer therapies work by blocking PD-L1 to boost immune attack on tumors, the new research suggests that enhancing PD-L1 signaling may help the body control severe respiratory viral infections, especially in people with T cell immunodeficiencies such as those with HIV or immunosuppression after chemotherapy.
“This discovery suggests that a pathway targeted in cancer could also be useful in infectious disease, but in the opposite way. Cancer therapies block PD-L1, whereas in flu, enhancing it may strengthen host defense,” said Silke Paust, a JAX professor and immunologist who directed the research.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.